Reduced-dose apixaban after left atrial appendage closure in atrial fibrillation

Trial details

Who runs it

National Medical Research Center for Therapy and Preventive Medicine

Trial code

NCT07575867

Record updated

8 May 2026

Original description

This is a prospective, non-randomized, observational cohort study conducted at the FSBI "NMRC TPM" of the Ministry of Healthcare of the Russian Federation. Left atrial appendage closure (LAAC) has been shown to be non-inferior to oral anticoagulation for preventing cardioembolic events in patients with atrial fibrillation. However, the optimal post-procedural antithrombotic regimen following LAAC remains unclear, with no consensus on evidence-based therapy. Given current trends in cardiology favoring reduced-intensity antithrombotic strategies, this study aims to contribute to the evidence base by evaluating whether LAAC followed by reduced-dose apixaban (2.5 mg BID) for 3 months with subsequent complete withdrawal of antithrombotic therapy is superior to long-term standard-dose DOAC therapy in patients with non-valvular atrial fibrillation.Read full original descriptionShow less

CLOT-LESS - CLOsure Tailored: LEss Antithrombotic Strategy After LAAC for Stroke Prevention

This is a prospective, non-randomized, observational cohort study conducted at the FSBI "NMRC TPM" of the Ministry of Healthcare of the Russian Federation. Left atrial appendage closure (LAAC) has been shown to be non-inferior to oral anticoagulation for preventing cardioembolic events in patients with atrial fibrillation. However, the optimal post-procedural antithrombotic regimen following LAAC remains unclear, with no consensus on evidence-based therapy. Given current trends in cardiology favoring reduced-intensity antithrombotic strategies, this study aims to contribute to the evidence base by evaluating whether LAAC followed by reduced-dose apixaban (2.5 mg BID) for 3 months with subsequent complete withdrawal of antithrombotic therapy is superior to long-term standard-dose DOAC therapy in patients with non-valvular atrial fibrillation.

Inclusion: Age ≥18 years; Documented nonvalvular AF (≥30 seconds on ECG within previous 12 months); CHA2DS2-VASc score ≥3 for women and ≥2 for men; Signed informed consent to participate in the study.

Exclusion: Inability to tolerate at least 3 months of apixaban therapy (for LAAC arm); Indications for antiplatelet therapy or therapy with P2Y12 inhibitors at the time of inclusion and/or the predicted/unpredicted occurrence of such indications during the entire study period; The patient had a myocardial infarction - MI with or without ST segment elevation (STEMI, NSTEMI) with or without intervention, within 30 days before LAAC; The patient had a stroke (of any cause, ischemic or hemorrhagic) within 30 days before LAAC; Major bleeding according to BARC criteria (type 3 and higher) within 30 days before LAAC or before randomization; Planned cardiac or non-cardiac surgical procedure within 30 days before or 90 days after LAAC. Minor procedures not requiring discontinuation of antithrombotic therapy are permitted (e.g., cardioversion, catheter ablation, cataract surgery); The presence of mechanical prosthetic heart valves, mitral stenosis of severe or moderate degree; Congenital or acquired haemostasis disorders, rheumatic heart disease or recurrent deep vein thrombosis; Severe liver failure, including cirrhosis and Child-Pugh Class C/D; NYHA class IV congestive heart failure; Contraindications for one of the treatment regimens prescribed by the study protocol (including allergic reactions); The patient has a heart tumor, active infection, signs of physiological tamponade; Left ventricular ejection fraction (LVEF) < 30%; Glomerular filtration rate (GFR) < 30 ml/min (stage IV or V chronic kidney disease) or dialysis patient; Platelet count < 100,000 x 109/l; Active indication for anticoagulation OTHER than atrial fibrillation at the time of enrollment and/or the predicted/unpredicted occurrence of such indications during the entire study period (e.g., mechanical valve, acute VTE, recent PE requiring >3 months anticoagulation); Active DVT requiring anticoagulation; Intracardiac thrombus before LAAC; Amyloid cardiomyopathy; The patient participates in another study, with the exception of observational studies without therapeutic interventions; Pregnant or breast-feeding patients, patients planning pregnancy during the study period; The LAAC procedure was unsuccessful or interrupted for technical reasons; PDL (peridevice leak) ≥ 3 mm; The documented life expectancy of the patient is less than 12 months.

ClinicalTrials.gov NCT07575867